Overview

A Phase I/II Study of AGA111 for Lumbar Interbody Fusion in Patients With Degenerative Disc Disease

Status:
Completed
Trial end date:
2022-07-13
Target enrollment:
Participant gender:
Summary
The objectives of the study are to evaluate the safety and preliminary efficacy of a single administration of AGA111 for lumbar interbody fusion in patients with degenerative disc disease.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Angitia Biopharmaceuticals